Actively Recruiting
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
Led by The University of Texas at Arlington · Updated on 2025-06-10
28
Participants Needed
2
Research Sites
417 weeks
Total Duration
On this page
Sponsors
T
The University of Texas at Arlington
Lead Sponsor
U
University of Texas, Southwestern Medical Center at Dallas
Collaborating Sponsor
AI-Summary
What this Trial Is About
Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. Recently, some studies have shown that a drug typically used to improve glucose control (pioglitazone) may also reduce sympathetic nerve activity and improve blood vessel function. The goal of this study is to determine whether a short-term treatment with pioglitazone can reduce sympathetic nerve impulses throughout the body in CKD patients.
CONDITIONS
Official Title
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- CKD patients classified as Stage 3 and 4 of National Kidney Foundation Classification with estimated glomerular filtration rate (GFR) between 15 and 59 mL/min/1.73 m2 according to the Modification of Diet in Renal Disease (MDRD) formula based on serum creatinine, age, gender, and race.
- Men and women 35 to 70 years of age
You will not qualify if you...
- Allergy to Glitazones
- Myocardial infarction
- Heart failure
- Angina
- History of kidney stones
- Liver disease (abnormal liver enzymes)
- Anemia (hemoglobin <8 g/dl)
- Cancer with current treatment
- Previous organ transplantation
- Immunosuppressant therapy
- Human immunodeficiency virus infection
- Pregnancy or lactating
- Current tobacco use
- Dilantin and oral contraceptive usage due to potential drug interaction with glitazones
- Self-identified history of hypoglycemia
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
University of Texas at Arlington
Arlington, Texas, United States, 76010
Actively Recruiting
2
UT Southwestern
Dallas, Texas, United States, 75390
Actively Recruiting
Research Team
P
Paul J Fadel, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here